Animal Allergies

Food Allergies

Allergy, Immunology, and ENT

Cardiovascular Diseases

Cardiology

Acne

Atopic Dermatitis

Dermatology

Emergency Medicine

Diabetes

Endocrinology

Formula

Nutrition

Obesity

Gastroenterology

Antibiotic Resistance

Bacterial Conjunctivitis

COVID-19

Influenza

Pneumonia

Sexually Transmitted Diseases

Vaccination and Immunization

Vaccines

Infectious Diseases

ADHD

Addiction

Antisocial Personality Disorder

Anxiety

Autism

Depression

Developmental/Behavioral Disorders

Psychiatry

Mental, Behavioral and Development Health

Concussion

Epilepsy

Headache

Neurology

Neonatal/Perinatology

OB/GYN

Pain

Drug Pipeline News

Pharmacology

Telemedicine

Practice Improvement

Asthma

Cystic Fibrosis

Respiratory

Rheumatology

News 

All News

PNP Corner

AAP News

Media

Around the Practice

Cure Connections

Expert Interviews

Insights

Medical World News

Peer Exchange

Peers & Perspectives

Podcasts

Webinars

Puzzler

Publications

Contemporary Pediatrics Journal

Supplements And Featured Publications

CME/CE

Resources

Handouts

Job Board

Conferences

Conference Coverage

Conference Listing

Partnerships

Subscribe

Editorial

Editorial Advisory Board

Writer’s Guidelines

Reference Guidelines

Meet the Editors

Tina Tan, MD, FAAP, FIDSA, FPIDS—editor in chief of 

, professor of pediatrics at Northwestern University’s Feinberg School of Medicine, Infectious Diseases attending at Lurie Children's Hospital of Chicago, and president of the Infectious Diseases Society of America.

Videos

 and joined the MJH Life Sciences team in December 2019. She graduated from Youngstown State University in 2019 with a bachelor's degree in journalism and a minor in political science. Prior to graduating, Morgan worked as the editor-in-chief of her college newspaper. She went on to work as an assignment editor at a broadcast news station in Youngstown, Ohio before joining 

 You can reach her at mpetronelli@mjhlifesciences.com.

In this video, the last in a 3-part series, panelists discuss future directions in the field and the importance of multispecialty collaboration.

RX Review: Collaborating to strengthen RSV prevention efforts

In this video, part 2 in a 3-part series, panelists discuss clesrovimab's recent approval and gaps in clinician education.

RX Review: Expanding options and addressing gaps in RSV prevention 

In this video, the first in a 3-part series, panelists discuss recent advancements in RSV management.

RX Review: RSV prevention and pediatric hospitalization

. He joined the brand in March of 2023 as an editor before being promoted to senior editor in January 2024. Fitch graduated from Youngstown State University in Youngstown, Ohio in 2020 with a degree in telecommunications and journalism. He started his career as a news and sports videographer before becoming an on-air sports anchor at the NBC-affiliated news station in Youngstown. Fitch briefly worked as a national content writer for a Chicago-based national television station before joining the 

team. He can be reached at: jfitch@mjhlifesciences.com.

Articles

The federal agency has assigned a target action date of January 31, 2026, for a decision. 

FDA accepts NDA for epinephrine sublingual film to treat type 1 allergic reactions

Contemporary Pediatrics connects pediatricians with peer-reviewed articles, guideline updates, and practice strategies for real-world clinical application.

About Us

Advertise

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Contemporary Pediatrics – Clinical News & Pediatrician Practice Tips

Facebook

LinkedIn

Instagram

Clinical

Gynecology

Infectious disease

Mental Health

Oncology

Rheumatoid Arthritis

Sexual Health

View More

1rem

Authors

A neurodevelopmentally impaired 6-year-old girl is referred for examination of asymptomatic skin lesions on the right forearm due to concern for possible child abuse. What's the diagnosis?

Puncture wounds and purpura

**Editor's Note** Please note that starting January 1, 2025, we will be switching to an online-exclusive publication process. This will allow us to publish case submissions quicker without having to deal with the variables that come along with print publication. All cases will still be eligible for print publication consideration, but publication in our print magazine is not guaranteed and will be up to the editor's discretion. 

Do you have a puzzling pediatric case that you’d like to share with the readers of 

We are looking for intriguing diagnoses that have stumped the experts—a diagnostic “Puzzler”—to help our physicians enhance their day-to-day practices. If you have such a story to tell, tell us.

Here’s what to do: Before you begin, we suggest that first you review the Puzzler 

https://www.contemporarypediatrics.com/case-studies

. Please note the specific style required for writing Puzzler manuscripts.

Next, prepare a draft of your case, including a summary of the presenting symptoms, a case overview, a 

table of the differential diagnosis (MANDATORY)

, and the special aspects of your case that qualify it as a Puzzler, and send it to us. Please note that the differential diagnosis table should also be discussed in the body text. We’ll review your draft and let you know what you need to add or revise before we send the manuscript to peer review for evaluation.

Puzzlers vary in length, and we suggest a minimum of 1,200 words up to a maximum of 2,000 words, but that is because of the complexity of some cases and whether some patients returned for many assessments before their diagnoses were determined. Also, some authors describe the pathophysiology of the differentials in great detail. Please also note no more than 3 authors are allowed per article.

What's most important is to show us the process that you used to analyze the case, including:

Why you decided to order certain tests and why you did not order others.

Peer consultations or why you elected to contact other specialists.

Lab values including vital signs or blood tests.

Labs and values if your patient was attended to in the emergency department or other hospital departments such as radiology or neurology.

Discussion related to the possible diagnoses.

Final diagnosis, treatment, prognosis, and follow-up.

Remember to indicate numbered citations within the body of the text and include a complete list of corresponding literature/references at the end of the manuscript. (Do not use any citation management programs or unlink them.) 

Limit references to 25. No references (unless it is a seminal study) can be older than 10 years.

We prefer primary research as references, but some cases are so obscure that authors will need to pull from a variety of sources. However, 

. Be advised that peer reviewers are adamant that the disease/disorder you describe was actually diagnosed and not determined by index of suspicion on the basis of ruling out various differentials. We use AMA11 as our publication style, which uses superscript citation numbers and a corresponding numbered reference list. Please create your citations and references in this style.  Check this recent article posted online at 

https://www.contemporarypediatrics.com/view/the-rx-of-adhd

 for examples of reference style. IMPORTANT NOTE WITH AMA 11TH EDITION: PLEASE PUT DOI OR WEBSITES/URLS AT THE END OF THE REFERENCE LINE.

When you send your draft manuscript, also 

. These image files must be high-resolution jpg or tiff files (minimum of 300 dpi) and as large in size as possible. We suggest a minimum of 7 horizontal inches. The images must be original photos with clear permissions to use, not images from copyrighted sources. Send as separate attachments with your e-mail submission; do not embed images into your manuscript document.

After we receive your manuscript, our editors and peer reviewers will review your draft and let you know if we accept your submission for publication. 

Puzzler is one of the departments for which we receive the most submissions, so it may be several months after submission before you receive feedback from us.

If we do accept your submission for publication, we will contact you with further instructions.

Send your submissions in Microsoft Word format to 

, via e-mail to mpetronelli@mjhlifesciences.com

Guidelines for PUZZLER, Contemporary Pediatrics

On June 15, 2025, the FDA announced the approval of a new presentation of ustekinumab-stba (Steqeyma; Celltrion), a biosimilar to ustekinumab (Stelara; Janssen Biotech), in a 45mg / 0.5mL solution in a single-dose vial for subcutaneous injection. The biosimilar is indicated for patients aged 6 to 17 years (< 60 kg) with plaque psoriasis (PsO) or psoriatic arthritis (PsA). With the approval, ustekinumab-stba offers all dosing forms of the reference product, according to a press release from Celltrion.

Previously, the FDA approved ustekinumab-stba 45mg/0.5mL, 90mg / mL in a single-dose prefilled syringe for subcutaneous injection, and 130mg / 26mL in a single-dose vial for intravenous infusion in December 2024. 

"Managing inflammatory diseases in pediatric patients can be particularly complex," said Hetal Patel, PharmD, MBA, vice president, Medical Affairs, Celltrion USA, in a statement. "The new dosage form and strength of STEQEYMA allow us to better meet the specific needs of young patients, giving physicians a valuable treatment option with flexibility, supported by a well-established safety and efficacy profile."

Approval for the biosimilar was based on the results from a phase 3 study in adults with moderate-to-severe PsO, where the primary endpoint was the rate of change in the Psoriasis Area and Severity Index for skin symptoms. Results demonstrated high similarity between ustekinumab-stba and ustekinumab, and have "no clinically meaningful differences in terms of safety and efficacy." 

on August 1, 2022, multiple biosimilars have been approved by the FDA. Click on the link below to read more about each biosimilar.  

On October 31, 2023, the FDA approved ustekinumab-auub (Wezlana; Amgen) as an interchangeable biosimilar to ustekinumab to treat patients aged 6 years and older with moderate-to-severe plaque psoriasis (candidates for phototherapy or systemic therapy) and for those with active psoriatic arthritis. 

On April 23, 2024, the FDA approved ustekinumab-aekn (SELARSDI; Alvotech and Teva Pharmaceuticals) to treat moderate-to-severe plaque psoriasis, as well as active psoriatic arthritis, in adults and pediatric patients aged 6 years and up. 

On July 9, 2024, the FDA approved ustekinumab-ttwe (Pyzchiva; Samsung Bioepis) for all indications of its reference ustekinumab. 

1. Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA (ustekinumab-stba), expanding dosing options for pediatric patients. Celltrion Inc. Press release. June 15, 2025. Accessed June 16, 2025. https://www.celltrionusa.com/board/newslist/40

2. Bader K. FDA approves ustekinumab to treat pediatric psoriatic arthritis. August 1, 2022. Accessed June 16, 2025. https://www.contemporarypediatrics.com/view/fda-approves-ustekinumab-to-treat-pediatric-psoriatic-arthritis

3. Fitch J. Ustekinumab biosimilar approved for children 6 years and up with plaque psoriasis, psoriatic arthritis. November 7, 2023. Accessed June 16, 2025. https://www.contemporarypediatrics.com/view/ustekinumab-biosimilar-approved-for-children-6-years-and-up-with-plaque-psoriasis-psoriatic-arthritis

4. Fitch J. Ustekinumab biosimilar approved to treat moderate to severe plaque psoriasis. Contemporary Pediatrics. April 23, 2024. Accessed June 16, 2025. https://www.contemporarypediatrics.com/view/ustekinumab-biosimilar-approved-to-treat-moderate-to-severe-plaque-psoriasi

5. Fitch J. FDA approves ustekinumab-ttwe as biosimilar for pediatric plaque psoriasis, active psoriatic arthritis. Contemporary Pediatrics. July 9, 2024. Accessed June 16, 2025. https://www.contemporarypediatrics.com/view/fda-approves-ustekinumab-ttwe-as-biosimilar-for-pediatric-plaque-psoriasis-active-psoriatic-arthritis

The approval for ustekinumab-stba now offers all dosage forms to the reference product, ustekinumab, and is indicated for patients aged 6 to 17 years.

News

FDA approves new presentation of ustekinumab-stba biosimilar for plaque psoriasis, psoriatic arthritis

 poll. Take a look at the following case below. After reading through the description, choose a multiple-choice answer and try to guess the correct patient diagnosis.

This case was presented by Giridhar Guntreddi, MD FAAP, FAPHM; Achuth Jayasankar Kondoor, Taylor Boske, Neelima P. Theella, MD, and Jayasree Vasudevannair, MD MPH FAAP. 

A healthy 12-month-old girl presented with one small skin lesion over the right heel (Image 1) for one month. On examination, her right lateral heel showed a round, white, pearl-like, hard, tiny lesion with a smooth appearance without any redness or itching. The patient's mother denied any pain, swelling, itching or fever. No significant travel, bites, heel stick injuries were reported in the history. No systemic symptoms suggested any underlying systemic diseases. The infant is closely monitored at subsequent well visits and re-checked. After 3 months, the child showed full resolution of the skin lesion over the heel area (Image 2).

Below, take your best guess at diagnosing this patient.

click here for the full case presentation, differential diagnosis, and correct patient diagnosis. 

Thank you for taking this Contemporary Pediatrics poll! Want more puzzler case studies? 

Can you diagnose this patient? Take our poll and find out! Then check back for the full case, differential diagnosis, and correct diagnosis.

Case Studies

Diagnose this infant with an asymptomatic pearl-like nodule on the heel

Music therapist Jenna Marcovitz discusses the role of pediatricians in making timely referrals to music therapy to support whole-child health.

  Connecting families to music therapy, with Jenna Marcovitz, MA

Music therapy can support pediatric patients across physical, emotional, and developmental domains—but first, families need to know the service exists. In a follow-up conversation to her 

on music therapy’s wide-ranging benefits for children, Jenna Marcovitz, MA, MT-BC, CCLS, RMT, director of Music Therapy UCLA Health and Children’s Music Fund/UCLA Music Therapy Internship Supervisor, emphasized the role of pediatricians in connecting families with these valuable services. Sharing even basic outcomes, such as support for speech and language development, can serve as an entry point into care.

“The first step, I think a great resource could be suggesting music therapy to patients and families—maybe they haven't even heard of it,” Marcovitz said. For families in the United States, she recommends the American Music Therapy Association’s online directory to locate board-certified professionals. 

“It’s a great starting point,” she said. “You can find organizations that provide music therapy or private practice professionals who can provide, even in-home music therapy services or telehealth music therapy services.” Globally, the World Federation of Music Therapy offers similar access to regional directories.

In an earlier conversation, Marcovitz outlined how music therapy is tailored to clinical goals and delivered through evidence-based interventions in a therapeutic relationship. “Although music entertainment can have therapeutic benefit, it isn’t always necessarily targeting a physical goal,” she explained previously. “In music therapy, that is what we do. In situations where you are working with patients and families that are under immense amounts of stress and existential and emotional distress, music therapy can provide a space for them to really process their emotions,” Marcovitz said. “We know emotions are connected to our whole body health.”

By collaborating with multidisciplinary healthcare teams and centering individualized goals, Marcovitz and her colleagues aim to integrate music therapy not just as a creative complement to care, but as a foundational component of holistic pediatric treatment.

Click here to watch Marcovitz explain how music therapy helps in pediatric care.

Disclosure: Jenna Marcovitz discloses grants/research funding for music therapy interns

Connecting families to music therapy, with Jenna Marcovitz, MA

In this video interview, Jenna Marcovitz, MA, MT-BC, CCLS, RMT, provides insight to music therapy and how it can benefit a wide range of pediatric patients.

Jenna Marcovitz, MA explains how music therapy helps in pediatric care

In this video interview, Jenna Marcovitz, MA, MT-BC, CCLS, RMT, director of Music Therapy UCLA Health and Children’s Music Fund/UCLA Music Therapy Internship Supervisor, explained why music therapy is and some common misconceptions associated with it. 

Marcovitz stated that music therapy is an evidence-based, clinically driven intervention that supports children across a range of medical and developmental needs. 

“Anyone and everyone can benefit from music therapy,” Marcovitz said. “Because it is so individualized and tailored to support clinical goals for the individual and their families and their communities. Premature infants demonstrate very significant physiological changes when supported with live music interventions by board-certified music therapists,” she explained. 

These benefits include improved oral feed coordination, increased weight gain, enhanced oxygen saturation, and faster hospital discharge. The mechanisms behind these outcomes are often rooted in rhythmic entrainment—how the brain and body align with the timing of music, facilitating developmental and autonomic regulation.

“It helps within the neurodivergent population and with individuals with developmental or sensory needs,” Marcovitz said, citing its contributions to behavioral modification and communication support. The broad mental health applications are especially notable, ranging from anxiety and depression support to improving emotional expression and resilience. “Pediatric oncology patients tend to really benefit from music therapy, from an emotional, social, psychological standpoint, as well as physically,” she said, referencing its use in managing pain, nausea, and other treatment side effects.

Marcovitz noted that the appearance of musical therapy could be misleading, and it goes beyond entertainment.

“Although music entertainment can have therapeutic benefit, it isn’t always necessarily specifically targeting a physical goal or some targeted emotional, psychological goal. In music therapy, that is what we do.”

Sessions are built around ongoing clinical assessments and evidence-based techniques—“within the therapeutic relationship, which is just as important, if not even more important than the music itself,” she said.

Jenna Marcovitz, MA, explains how music therapy helps in pediatric care

Beginning in mid-May, the FDA, Health and Human Services (HHS), and the CDC outlined a new COVID-19 vaccine framework and announced on May 27 the removal of the vaccine from the CDC immunization schedule for healthy children and pregnant individuals. However, according to the CDC's Child Immunization schedule that was updated on May 29, healthy individuals aged 6 months to 17 years who are not moderately or severely immunocompromised can receive the vaccine through a "shared clinical decision-making process."

Below is a timeline recap of these changes and announcements. 

May 20, 2025: FDA announces new COVID-19 policy for children 

In this article, we recap a timeline of recent federal agency changes to routine COVID-19 vaccination intended for the pediatric population. 

Charles J. Hyman, MD, FAAP

Articles

Latest Updated Articles